Progestogen orchestrates estrogen signaling and influences outcomes of endocrine resistance in breast cancer
PR-positive cancers, PR-negative cancers, breast cancer
BREAST CANCER
The presence of PR in breast cancer is a well-established prognostic factor, with patients with PR-positive cancers tending to have a better prognosis than those with PR-negative cancers [The interplay between progesterone and estrogen signaling in breast cancer is complex, and recent research suggests that the use of combinatorial endocrine therapies requires careful consideration to avoid pro-tumorigenic outcomes. While progesterone has shown promise in modulating the efficacy of endocrine therapies such as tamoxifen, fulvestrant, and giredestrant against 